These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37650722)

  • 1. Comparison of 2 Immunosuppression Minimization Strategies in Kidney Transplantation: The ALLEGRO Trial.
    van den Born JC; Meziyerh S; Vart P; Bakker SJL; Berger SP; Florquin S; de Fijter JW; Gomes-Neto AW; Idu MM; Pol RA; Roelen DL; van Sandwijk MS; de Vries DK; de Vries APJ; Bemelman FJ; Sanders JSF
    Transplantation; 2024 Feb; 108(2):556-566. PubMed ID: 37650722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Steroid Withdrawal Compared With Standard Immunosuppression in Kidney Transplantation - Interim Analysis of the Amsterdam-Leiden-Groningen Randomized Controlled Trial.
    van Sandwijk MS; de Vries APJ; Bakker SJL; Ten Berge IJM; Berger SP; Bouatou YR; de Fijter JW; Florquin S; Homan van der Heide JJ; Idu MM; Krikke C; van der Pant KAMI; Reinders ME; Ringers J; van der Weerd NC; Bemelman FJ; Sanders JS
    Transplant Direct; 2018 Jun; 4(6):e354. PubMed ID: 30123827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C; Suwelack B; Dragun D; Schenker P; Hauser IA; Witzke O; Hugo C; Kamar N; Merville P; Junge M; Thaiss F; Nashan B;
    Kidney Int; 2019 Jul; 96(1):231-244. PubMed ID: 31027892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data.
    Qazi Y; Shaffer D; Kaplan B; Kim DY; Luan FL; Peddi VR; Shihab F; Tomlanovich S; Yilmaz S; McCague K; Patel D; Mulgaonkar S
    Am J Transplant; 2017 May; 17(5):1358-1369. PubMed ID: 27775865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal.
    Tönshoff B; Tedesco-Silva H; Ettenger R; Christian M; Bjerre A; Dello Strologo L; Marks SD; Pape L; Veldandi U; Lopez P; Cousin M; Pandey P; Meier M
    Am J Transplant; 2021 Jan; 21(1):123-137. PubMed ID: 32406111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial.
    Bang JB; Oh CK; Ju MK; Kim SJ; Yu HC; Lee SH
    Transplant Proc; 2020; 52(1):133-139. PubMed ID: 31898939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belatacept for kidney transplant recipients.
    Masson P; Henderson L; Chapman JR; Craig JC; Webster AC
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010699. PubMed ID: 25416857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT.
    Haupenthal F; Rahn J; Maggi F; Gelas F; Bourgeois P; Hugo C; Jilma B; Böhmig GA; Herkner H; Wolzt M; Doberer K; Vossen M; Focosi D; Neuwirt H; Banas M; Banas B; Budde K; Viklicky O; Malvezzi P; Rostaing L; Rotmans JI; Bakker SJL; Eller K; Cejka D; Pérez AM; Rodriguez-Arias D; König F; Bond G;
    Trials; 2023 Mar; 24(1):213. PubMed ID: 36949445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and metabolic advantages of steroid withdrawal after 6 months posttransplant in de novo kidney transplantation: A 1-year prospective cohort study.
    Bang JB; Oh CK; Kim YS; Kim SH; Yu HC; Kim CD; Ju MK; So BJ; Lee SH; Han SY; Jung CW; Kim JK; Ahn HJ; Lee SH; Jeon JY
    Immun Inflamm Dis; 2022 Mar; 10(3):e576. PubMed ID: 34913271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Everolimus Plus Standard-Dose Tacrolimus Immunosuppression in De Novo Kidney Transplant: A Retrospective, Single-Center Study of 225 Transplants.
    Okabe Y; Noguchi H; Sato Y; Mei T; Kaku K; Ueki K; Tsuchimoto A; Nakamura M
    Exp Clin Transplant; 2022 Mar; 20(4):362-369. PubMed ID: 35475420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study).
    Stumpf J; Thomusch O; Opgenoorth M; Wiesener M; Pascher A; Woitas RP; Suwelack B; Rentsch M; Witzke O; Rath T; Banas B; Benck U; Sommerer C; Kurschat C; Lopau K; Weinmann-Menke J; Jaenigen B; Trips E; Hugo C
    Nephrol Dial Transplant; 2023 Dec; 39(1):141-150. PubMed ID: 37391381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
    Stratta RJ; Alloway RR; Hodge E; Lo A;
    Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.